Hot or not - 5 early stage trials with different agents and targets
5 abstracts to watch out for at the ASCO22 meeting in Chicago
Highlights from the KRAS front with three different company products not named sotorasib or adagrasib
Going beyond both G12C and G12D to a plethora of new targets and combination approaches
All aboard to hear more about novel targeted therapy combination strategies...
A lion roar or whimper at the prospect of KRASi plus IO trials?
The latest on bispecifics and protein degraders
Hot topics to follow at AACR22
Trick or treat? A look at the sotorasib data in PDAC.
Cracking the tumour code
A look at some recent phase 2 data in the KRAS niche in the context of the broader landscape
Preview of what to watch out for at ASCO GI22
What to watch out for in 2022
A dozen early stage biotechs in the RAS/RAF pathway to watch out for
A number of new developments to consider in the KRAS niche
A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs
SITC 2021 Preview
Where next in the ever expanding KRAS runners and riders?
What can we learn from KRASi combinations? Do any stand out?
One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…
Developmental Therapeutics is hard, how do companies go about finding a way forward?
A look at the controversial adagrasib data in mCRC at ESMO21
Highlights from WCLC Day 1
A look at some cool science and novel strategies for tackling an intractable target
Can a genomic signature help select patients more accurately for DDR therapies?
What's hot at WCLC21?
It's time to tackle some intractable targets in oncology and elsewhere...
What are Novartis up to these days with their oncology pipeline and what are they excited about?
Update on the Novartis SHP2 inhibitor at ASCO21
Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!
New developments on the KRAS and SHP2 front
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
Noteworthy AACR21 on-demand presentations.
Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!
Getting to the centre of things with protein degradation
Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?
Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore
Important developments on the GI cancer front to watch out for
W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on
We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat
The devil is in the finer details...
It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…
The trials and tribulations of targeted agents in developmental therapeutics
An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.
Winners, losers and risers... who goes where in the final analysis?
What to watch out for this weekend in targeted therapies and early stage new product development
A look at progress and new developments in cancer biomarker developments
Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies
Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer
Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…
What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?
A novel epigenetic target may have far-reaching outcomes for cancer patients
Highlights from several solid tumour trials in both early and late stage disease.
A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences
Commentary on Day 1 of the AACR20 Virtual Meeting
Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2
Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus
An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche
Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?
Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.
How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.
KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib
Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?
On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...
How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...
We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.
Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
Drugging the undruggable with creative approaches to molecule development
A look at what we can learn from some recently published new papers in the oncology space.